{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.05","upperLimit":"1530","value":"445.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"288"}],"units":"Participants"}],"title":"ARV-471: Cycle 2 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.5","upperLimit":"2260","value":"795.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"274"}],"units":"Participants"}],"title":"ARV-471: Cycle 2 Day 1 (5 to 7 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.5","upperLimit":"1680","value":"453.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"}],"units":"Participants"}],"title":"ARV-471: Cycle 3 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"151","upperLimit":"2170","value":"743.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"}],"units":"Participants"}],"title":"ARV-471: Cycle 3 Day 1 (5 to 7 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"1370","value":"440.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"title":"ARV-471: Cycle 5 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"1130","value":"466.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"}],"units":"Participants"}],"title":"ARV-471: Cycle 7 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"628","value":"193.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"288"}],"units":"Participants"}],"title":"ARV-473: Cycle 2 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.3","upperLimit":"700","value":"225.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"274"}],"units":"Participants"}],"title":"ARV-473: Cycle 2 Day 1 (5 to 7 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.10","upperLimit":"611","value":"193.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"}],"units":"Participants"}],"title":"ARV-473: Cycle 3 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.0","upperLimit":"655","value":"214.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"}],"units":"Participants"}],"title":"ARV-473: Cycle 3 Day 1 (5 to 7 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"561","value":"188.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"title":"ARV-473: Cycle 5 Day 1 (-4 to 0 hours)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"464","value":"186.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"}],"units":"Participants"}],"title":"ARV-473: Cycle 7 Day 1 (-4 to 0 hours)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"288"}],"units":"Participants"}],"description":"Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.","dispersionType":"Full Range","groups":[{"description":"Participants were randomized to receive vepdegestrant 200 milligrams (mg) orally, once daily on Days 1 to 28 of each 28-day cycle. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.","id":"OG000","title":"Vepdegestrant (ARV-471)"}],"paramType":"MEDIAN","populationDescription":"PK concentration set included all participants who were in the Safety Analysis Set and had at least 1 concentration of either ARV-471 or ARV-473. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and \"Number analyzed\" signifies participants evaluable for a specified timepoint.","reportingStatus":"POSTED","timeFrame":"Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3","title":"Plasma Concentration of ARV-471 and Its Epimer ARV-473","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}